Stock screener

CBIO

Conviction 65HealthcareScan · Mon, Aug 10, 2026
CBIO$17.33+2.91%
ResistanceSupportVol 14
63 bars
Vol MA14 373.57K
May 11May 28Jun 16Jul 6Jul 23Aug 10
CRESCENT BIOPHARMA, INC.PHARMACEUTICAL PREPARATIONSwww.crescentbiopharma.com
Price17.33
Change+2.91%
Gap+1.04%
Rel volume4.11×
Avg volume484.05K
Avg $ vol7.74M
SMA 2015.85
SMA 5016.97
SMA 20015.01
Price vs 50+2.11%
Price vs 200+15.48%
MA stackbullish
50/200 cross
Supertrenddown · 18.64
RSI (14)56
MACD hist0.25
MACD crossbull · 4d
Stoch %K / %D88 / 76
ADX (14)15
+DI / −DI25 / 15
RSI divergenceBullish
MACD divergenceBullish
ATR %+7.37%
ADR %8.07%
52w high26.98
52w low8.94
From 52w high-35.77%
Above 52w low+93.85%
New 52w highNo
SqueezeFired
Bollinger width21.84%
%B0.93
Donchian pos87.66%
Donchian high17.80
Donchian low13.99
AVWAP (52w high)18.05
vs AVWAP high-4.01%
AVWAP (52w low)17.02
vs AVWAP low+1.84%
OBV trendUp
Chaikin MF (20)0.03
Today vs 20d4.11×
Avg vol (14d)373.57K
Avg vol (20d)484.05K
Avg $ vol (20d)7.74M
Market cap643.7M
RS 3m (vs SPY)-12.14%
RS 6m (vs SPY)+64.84%
RS line new highNo
Trend template6/8
Technical rank81.3
1 week+16.54%
1 month-0.06%
3 months-7.62%
6 months+82.23%
1 year+57.55%
YTD+56.41%
P/E-4.18
P/B3.94
P/S59.36
P/FCF-8.88
EPS-0.5900
Div yield
ROE-94.30%
ROA-84.23%
Debt/Eq
Current9.66
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth-306.40%
Price target29.50
Target upside70.23%
Analyst ratingBuy
Institutional76.19%
Ent. value472.11M
Revenue0
Net income-24.84M
Gross profit
Free cash flow-72.45M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out
Employees44
ListedMon, Jun 16, 2025
Free float18.11M
Float %65.7%
Short interest3.74M
Days to cover9.7d
Short volume38.1%
Squeeze score80 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.74 vs −$0.78
Last surprise+5.1% beat
Setup gradeB
Conviction65 / 100
Pattern quality
Tech rank81.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance19.03
Support14.23
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CBIO

All disclosures →
No recent disclosed trades by Congress in CBIO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CBIO · 8 buys

InsiderSideShares
Violin Jonathan
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Moran Susan
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Fairmount Healthcare Fund II L.P.
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Fairmount Funds Management LLC
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Lubner David Charles
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Harwin Peter Evan
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Kiselak Tomas
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K
Balcom Alexandra
Director · Stock Option (Right to Buy) · 2026-06-02
Grant11.05K

SEC filings

EDGAR filings in CBIO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.